AU2020302784A1 - Method of reconstituting liposomal Annamycin - Google Patents

Method of reconstituting liposomal Annamycin Download PDF

Info

Publication number
AU2020302784A1
AU2020302784A1 AU2020302784A AU2020302784A AU2020302784A1 AU 2020302784 A1 AU2020302784 A1 AU 2020302784A1 AU 2020302784 A AU2020302784 A AU 2020302784A AU 2020302784 A AU2020302784 A AU 2020302784A AU 2020302784 A1 AU2020302784 A1 AU 2020302784A1
Authority
AU
Australia
Prior art keywords
annamycin
liposomal
saline
bag
vial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020302784A
Other languages
English (en)
Inventor
Donald Picker
Waldemar Priebe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Moleculin Biotech Inc
Original Assignee
University of Texas System
University of Texas at Austin
Moleculin Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin, Moleculin Biotech Inc filed Critical University of Texas System
Publication of AU2020302784A1 publication Critical patent/AU2020302784A1/en
Priority to AU2024203593A priority Critical patent/AU2024203593B2/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277Preparation processes; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
AU2020302784A 2019-06-28 2020-06-25 Method of reconstituting liposomal Annamycin Pending AU2020302784A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024203593A AU2024203593B2 (en) 2019-06-28 2024-05-29 Method of reconstituting liposomal annamycin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962868190P 2019-06-28 2019-06-28
US62/868,190 2019-06-28
PCT/US2020/039621 WO2020264161A1 (en) 2019-06-28 2020-06-25 Method of reconstituting liposomal annamycin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024203593A Division AU2024203593B2 (en) 2019-06-28 2024-05-29 Method of reconstituting liposomal annamycin

Publications (1)

Publication Number Publication Date
AU2020302784A1 true AU2020302784A1 (en) 2022-01-20

Family

ID=74061076

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020302784A Pending AU2020302784A1 (en) 2019-06-28 2020-06-25 Method of reconstituting liposomal Annamycin
AU2024203593A Active AU2024203593B2 (en) 2019-06-28 2024-05-29 Method of reconstituting liposomal annamycin

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024203593A Active AU2024203593B2 (en) 2019-06-28 2024-05-29 Method of reconstituting liposomal annamycin

Country Status (15)

Country Link
US (2) US12257262B2 (https=)
EP (1) EP3990041B1 (https=)
JP (1) JP7830131B2 (https=)
KR (1) KR20220027941A (https=)
CN (2) CN114728101B (https=)
AU (2) AU2020302784A1 (https=)
BR (1) BR112021026480A2 (https=)
CA (1) CA3144443A1 (https=)
ES (1) ES3049663T3 (https=)
IL (1) IL289433B1 (https=)
MX (1) MX2021015667A (https=)
PL (1) PL3990041T3 (https=)
SG (1) SG11202113005SA (https=)
TW (2) TW202500161A (https=)
WO (1) WO2020264161A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3049663T3 (en) 2019-06-28 2025-12-17 Univ Texas Method of reconstituting liposomal annamycin
KR20220027969A (ko) 2019-06-28 2022-03-08 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 프리리포솜 아나마이신 동결건조물의 제조
KR20220103992A (ko) * 2019-11-21 2022-07-25 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 리포솜 아나마이신에 의한 폐 표적화 항암 요법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927571A (en) * 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US4863739A (en) 1987-05-19 1989-09-05 Board Of Regents, The University Of Texas System Liposome compositions of anthracycline derivatives
IS1685B (is) * 1990-12-11 1998-02-24 Bracco International B.V. Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum
US5902604A (en) * 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
WO2001032145A1 (en) * 1999-10-29 2001-05-10 Board Of Regents, The University Of Texas System Method of cancer treatment
EP2314285B2 (en) * 2003-02-14 2019-09-18 Children's Hospital & Research Center at Oakland Lipophilic drug delivery vehicle and methods of use thereof
PL2544537T3 (pl) * 2010-03-10 2017-10-31 Cempra Pharmaceuticals Inc Pozajelitowe preparaty antybiotyków makrolidowych
WO2013055874A2 (en) * 2011-10-14 2013-04-18 Genentech, Inc. Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
EP3572071A1 (en) * 2011-10-21 2019-11-27 Jazz Pharmaceuticals Research LLC Lyophilized liposomes
US8926994B2 (en) 2011-12-07 2015-01-06 The Methodist Hospital Research Institute Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
CN107569508A (zh) * 2016-07-05 2018-01-12 江苏竞诺择生物医药科技有限公司 一种治疗造血系统增殖性疾病的药用组合物
WO2018048752A1 (en) 2016-09-09 2018-03-15 Irisys, Inc. Lipsomal anticancer compositions
WO2019023873A1 (zh) * 2017-07-31 2019-02-07 江苏竞诺择生物医药科技有限公司 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物
MA53565A (fr) 2018-09-04 2021-07-14 Minerva Neurosciences Inc Procédés d'utilisation d'un composé phénoxypropylamine pour le traitement de la douleur
ES3049663T3 (en) 2019-06-28 2025-12-17 Univ Texas Method of reconstituting liposomal annamycin
KR20220027969A (ko) 2019-06-28 2022-03-08 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 프리리포솜 아나마이신 동결건조물의 제조
KR20220103992A (ko) 2019-11-21 2022-07-25 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 리포솜 아나마이신에 의한 폐 표적화 항암 요법

Also Published As

Publication number Publication date
EP3990041A1 (en) 2022-05-04
TW202500161A (zh) 2025-01-01
EP3990041B1 (en) 2025-08-06
CN114728101B (zh) 2023-07-14
CN114728101A (zh) 2022-07-08
PL3990041T3 (pl) 2026-02-23
US12257262B2 (en) 2025-03-25
IL289433A (en) 2022-02-01
US11980634B2 (en) 2024-05-14
JP2023523872A (ja) 2023-06-08
CA3144443A1 (en) 2020-12-30
WO2020264161A1 (en) 2020-12-30
JP7830131B2 (ja) 2026-03-16
SG11202113005SA (en) 2021-12-30
TW202114704A (zh) 2021-04-16
BR112021026480A2 (pt) 2022-02-08
EP3990041A4 (en) 2023-07-12
US20240024345A1 (en) 2024-01-25
MX2021015667A (es) 2022-04-18
CN116785242A (zh) 2023-09-22
KR20220027941A (ko) 2022-03-08
US20220105116A1 (en) 2022-04-07
TWI857086B (zh) 2024-10-01
IL289433B1 (en) 2026-01-01
AU2024203593B2 (en) 2025-08-14
ES3049663T3 (en) 2025-12-17
AU2024203593A1 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
US11980634B2 (en) Method of reconstituting liposomal annamycin
US11951118B2 (en) Preparation of preliposomal annamycin lyophilizate
HK40073244A (en) Method of reconstituting liposomal annamycin
HK40073244B (en) Method of reconstituting liposomal annamycin
JP6850788B2 (ja) 硫酸ビンクリスチンリポソーム注射のための即時使用可能な製剤形態
CN114712309B (zh) 一种人参皂苷多西他赛脂质体、其制备方法和应用
CA3142510C (en) Preparation of preliposomal annamycin lyophilizate
AU2014200717B2 (en) Liposome composition
HK40009643B (en) Liposomal formulation for use in the treatment of cancer